India's pharmaceutical sector is one of the world's largest by volume, supplying generic drugs globally and serving a large domestic formulations market. Companies range from API manufacturers to branded generics exporters with significant US FDA exposure. The sector is defensively oriented but subject to regulatory risk — USFDA inspections, pricing pressure in the US generics market, and domestic price controls are key variables.
| # | Company | JayScore | Signal | Research |
|---|---|---|---|---|
| 1 |
Aurobindo Pharma Limited
AUROPHARMA
|
85 | High Conviction | View → |
| 2 |
Divi's Laboratories Limited
DIVISLAB
|
85 | High Conviction | View → |
| 3 |
Glenmark Pharmaceuticals Limited
GLENMARK
|
78 | High Conviction | View → |
| 4 |
Sun Pharmaceutical Industries Limited
SUNPHARMA
|
67 | Positive Setup | View → |
| 5 |
Cipla Limited
CIPLA
|
67 | Positive Setup | View → |
Check the sector regime. Trading with the trend is better than against it — a Bullish regime means the sector's relative strength is rising vs the Nifty.
Use the JayScore to shortlist — higher-scored stocks have stronger technical momentum + fundamental quality. Scores above 65 are historically the highest win-rate band.
Open the individual stock page to see the full Research Score Insight — each stock gets a unique engine-generated paragraph explaining the key drivers.
Free account — run 5 screener queries per day, see scores for every NSE stock, track your watchlist.
Create Free Account →